CDKN1A and neoplasm: Xu et al. found that in gefitinib-resistant tumor cells, UCA1 binds directly to EZH2, increasing H3K27me3 levels at the CDKN1A promoter region and reducing downstream CDKN1A expression, thereby mediating gefitinib resistance101.